Katharina Kreymborg

Dr Katharina (Nina) Kreymborg is an experienced drug discovery scientist. Her professional passion is turning exciting scientific ideas and novel concepts into actual drugs. Nina held different positions in big pharma, biotech and venture capital, allowing her to experience and understand this journey from very different perspectives.  

Nina trained as a cancer immunotherapist in Jim Allison’s lab at Memorial Sloan Kettering Cancer Center and subsequently joined pharma research and early clinical development at Roche. At Roche, and later at Morphosys, she led and supported multiple projects at different stages between target assessment and early clinical development, including targeted cytokines, T-cell engagers, checkpoint inhibitors, and myeloid activators. Most recently, Nina acted as an investor and company builder, identifying promising therapeutic concepts and building biotech start-up companies from the ground at Versant Ventures and now at Curie.Bio. In her current role, she works closely with founders to transform exciting scientific ideas into novel therapeutics for patients’ benefit.